Innovent Biologics (HKEX: 01801) has signed a collaboration agreement with fellow Chinese biotech firm Shenogen Pharma to evaluate the combination therapy of Innovent's Tyvyt (sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody with Shenogen's SNG1005, in patients with advanced cancer.
Market reaction was slightly negative, with Innovent’s shares closing the day down 2.24% at HK$23.95.
SNG1005 is a conjugate of angiopep-2 and paclitaxel that Shenogen licensed from overseas. Multiple Phase II clinical trials have been completed in the USA, and its Phase III clinical trial protocol has been approved by the US Food and Drug Administration. Shenogen has the full development and commercialization rights for SNG1005 in Greater China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze